AUTHORS
Mathew G. Angelos, MD, PhD, Marc Schwartz, MD2, Navin Pinto, MD3, Michael Verneris, MD4, Daniel Pollyea, MD5, Christine M. McMahon, MD6, Jonathan Gutman, MD7, Maria Laura Amaya, MD PhD8, Andrew Kent, MD, PhD9, Bonnie Yates, MS, CPNP-AC10, Cheri Adams, MSHS, RN, RAC11, Katie Anttila, RN12, Jessica Dell-Martin13, Angela Ohm14, Louisa Wirthlin15, Pradyot Dash, PhD16, Rimas Orentas, PhD17, Kimberly Jordan18, Terry Fry, MD19
AFFILIATIONS
1 The University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
2 NYU Grossman Long Island School of Medicine, Mineola, New York, United States, The University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
3 Children's Hospital Colorado, Aurora, Colorado, United States
4 Children's Hospital Colorado, Aurora, Colorado, United States
5 The University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
6 The University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
7 The University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
8 The University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
9 The University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
10 The University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
11 The University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
12 The University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
13 The University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
14 The University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
15 Lentigen Technology Inc., Miltenyi Corporation, Gaithersburg, Maryland, United States
16 Lentigen Technology Inc., Miltenyi Corporation, Gaithersburg, Maryland, United States
17 Lentigen Technology Inc., Miltenyi Corporation, Gaithersburg, Maryland, United States
18 The University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
19 Children's Hospital Colorado, Aurora, Colorado, United States
ABSTRACT
Background: CD19-directed chimeric antigen receptor (CAR) T cell therapy (CART19) can induce durable remissions in heavily pre-treated adults with B-cell acute lymphoblastic leukemia (B-ALL). However, commercial CART19 therapies are not FDA-approved earlier in the course of B-ALL treatment as a definitive consolidation strategy once first complete remission (CR1) is achieved. Patients (pts) with measurable residual disease (MRD)-positive CR1 following induction or early consolidation are at high risk for relapse despite contemporary treatment approaches. We hypothesized that earlier administration of CART19 is a safe and efficacious modality for adult pts with MRD-positive CR1.
Study Design: We performed a single center, phase I/Ib clinical trial (NCT05535855) using UCD19 CAR T cell therapy (UCD19) for pts ≥18 years of age with B-ALL in MRD-positive CR1. For Philadelphia-chromosome-negative (Ph-) B-ALL, MRD was defined as ≥0.01% B-lymphoblasts by multiparameter flow cytometry (MFC) or >0 clonal sequences by next generation sequencing (NGS, ClonoSEQ) after 28 days of remission-induction therapy. For Philadelphia-chromosome-positive (Ph+) B-ALL, MRD included less than a complete molecular remission (undetectable BCR::ABL1 by RT-PCR) after 56 days of TKI + steroids ± blinatumomab. Pts were apheresed for UCD19 manufacturing, an investigational, second-generation, anti-CD19 4-1BB-based CAR with a unique TNFRSF19-derived transmembrane domain, and IL7/IL15 culture that enriches for less-differentiated T cell phenotypes. Two dose levels (DL1: 0.5x108; DL2:1.5x108 CD3+CAR+ cells) were tested in phase I to determine the maximum tolerated dose for phase Ib. All pts received fludarabine + cyclophosphamide lymphodepletion. Bridging therapy between apheresis and UCD19 infusion was allowed. Relapse was defined as ≥5% blasts or emergence of MRD by MFC or NGS after achieving MRD-negative CR. Primary endpoints were (1) safety/tolerability and (2) 12- and 24-month relapse free survival (RFS).
Results: From 1/2/2024-6/30/26, 18 pts enrolled and 16 pts received UCD19 (DL1: n=2, DL2: n=14). Median age was 44 years (range: 18-72) and median time from diagnosis to UCD19 infusion was 103.5 days (range: 71-169). Two pts were Ph+, four were Ph-like (2 CRLF2r, 1 IGH::EPOR, 1 PDGFRB::EBF1), three TP53mut, two KMT2Ar, and one MEF2D::BCL9. 14/16 (87.5%) pts received bridging therapy: TKI (n=3), CALGB10403 interim maintenance (n=3), low-intensity chemotherapy (n=6), or inotuzumab (n=2); no pts received blinatumomab. Before UCD19 infusion, 12/16 (75%) pts remained MRD-positive by NGS, including 4/16 (25%) pts also positive by MFC.
During dose-finding (n=10), two DLTs occurred (both G4 neutropenia >D+42) that resolved with G-CSF; no additional DLTs have occurred during dose-expansion. Overall, only 2/16 (12.5%) pts developed G1 CRS; no ICANS or IEC-HS occurred.
All 15/15 (100%) evaluable pts achieved an MRD-negative CR by D+28 that persisted through 3 months after UCD19 infusion. This correlated with UCD19 kinetics, with median time to peak expansion of 14.0 days (IQR: 7.0-15.0) and mean CMax 56.9±17.0 CD3+ cells/uL, despite low disease burden. At 6 months, 9/13 (69.2%) pts remained MRD-negative CR, 3/13 pts (23.1%) had MRD-positive CR (MFC-/NGS+), and 1/13 pt (7.7%) developed CD19+ morphologic relapse. At 12 months, 6/7 (85.7%) pts remained MRD-negative CR and 1/7 (14.3%) pt developed MRD-positive CR (MFC-/NGS+). At data cut, all 15 evaluable pts were included in the RFS analysis, with 12 pts at risk at 12 months. Median follow-up by reverse Kaplan-Meier method was 18 months (95% CI, 6-24), and the estimated 12-month RFS was 83.3% (95% CI, 48.2%-95.6%). Three pts remain in an MRD-negative CR beyond 2 years after UCD19 infusion. Nine pts continue on study without further B-ALL treatment and three pts remain on maintenance TKI post-UCD19.
Interestingly, loss of B cell aplasia (BCA; ≥10 CD19+ cells/uL) did not reliably predict relapse (2/5 (40%) relapsed pts). By 6 months, 4/9 (44.4%) pts in MRD-negative CR lost BCA; four pts were reinfused with UCD19 within the first 6 months of initial UCD19 infusion, which failed to restore long-term BCA.
Significance: UCD19 as consolidation for adults with B-ALL in MRD-positive CR1 is safe and shows promising long-term MRD-negative CR conversion in this poor-risk enriched B-ALL cohort. This strategy may mitigate the need for prolonged chemotherapy, immunotherapy, and potentially allogeneic stem cell transplant.
DISCLOSURES
Mathew G. Angelos, MD, PhD: No relevant conflicts of interest to declare.